Overview of the management of differentiated thyroid cancer

被引：41

作者：

Fernandes J.K. ^{[1
]}

Day T.A. ^{[1
]}

Richardson M.S. ^{[1
]}

Sharma A.K. ^{[1
]}

机构：

[1] The Medical Univ. of South Carolina, Charleston, SC 29425

来源：

Current Treatment Options in Oncology | 2005年 / 6卷 / 1期

关键词：

Thyroid Cancer; Thyroid Carcinoma; Papillary Thyroid Carcinoma; Thyroid Nodule; Thyroid Stimulate Hormone;

D O I：

10.1007/s11864-005-0012-3

中图分类号：

学科分类号：

摘要：

Thyroid cancer is an uncommon tumor accounting for roughly 1% of all new malignancies. Differentiated (ie, papillary or follicular) thyroid carcinoma is usually asymptomatic, and frequently appears as a solitary thyroid nodule but few show cervical lymphadenopathy or metastasis to lung, bone, or liver. Fine needle aspiration (FNA) is recommended in the initial diagnostic test. Depending on the size of the lesion and other associated risk factors, most patients are treated with total or near total thyroidectomy. Postoperative radioiodine ablation is performed when tumor has a potential for recurrence. Recurrence rates and cancer-specific mortality is decreased by suppressing thyroid stimulating hormone (TSH). Long-term surveillance and follow-up with physical examination every 3 to 6 months for 2 years and then annually if patient remains cancer free. Whole body iodine scans are done every 12 months for follow-up until one negative scan (either withdrawal of thyroid hormone or rhodium complex [rh]-TSH). Thyroglobulin measurements (with antithyroglobulin antibodies) and ultrasound neck are suggested at 6 and 12 months and then annually if disease free. Copyright © 2005 by Current Science Inc.

引用

页码：47 / 57

页数：10

共 54 条

[41]

Mazzaferri E.L., Young R.L., Papillary thyroid carcinoma: A 10-year follow-up report of the impact of therapy in 576 patients, Am. J. Med., 70, pp. 511-518, (1981)

[42]

Tsang R.W., Brierley J.D., Simpson W.J., Et al., The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma, Cancer, 82, pp. 375-388, (1998)

[43]

Simpson W.J., Panzarella T., Carruthers J.S., Et al., Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients, Int. J. Radiat. Oncol. Biol. Phys., 14, pp. 1063-1075, (1988)

[44]

Philips P., Hanzen C., Andry G., Et al., Postoperative irradiation for thyroid cancer, Eur. J. Surg. Oncol., 19, pp. 399-404, (1993)

[45]

Ford D., Giridharan S., McConkey C., Et al., External beam radiotherapy in the management of differentiated thyroid cancer, Clin. Oncol. (R. Coll. Radiol.), 15, pp. 337-341, (2003)

[46]

Ahuja S., Ernst H., Chemotherapy of thyroid carcinoma, J. Endocrinol. Invest., 10, pp. 303-310, (1987)

[47]

Droz J.P., Schlumberger M., Rougier P., Et al., Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy, Tumori, 76, pp. 480-483, (1990)

[48]

Williams S.D., Birch R., Einhorn L.H., Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial, Cancer Treat. Rep., 70, pp. 405-407, (1986)

[49]

Schmutzler C., Koehrle J., Innovative strategies for the treatment of thyroid cancer, Eur. J. Endocrinol., 143, pp. 15-24, (2000)

[50]

Grunwald F., Menzel C., Bender H., Et al., Redifferentiation therapy-induced radioiodine uptake in thyroid cancer, J. Nucl. Med., 39, pp. 1903-1906, (1998)

← 1 2 3 4 5 6 →